Received Nov 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | DY3K7 | — |
administered a dose of Boostrix to patient after the temperature excursion; This non-serious case was reported by a nurse via call center representative and described the occurrence of incorrect storage of drug in a 26-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number DY3K7, expiry date 14-JUN-2027) for prophylaxis. On an unknown date, the patient received Boostrix. On an unknown date, an unknown time after receiving Boostrix, the patient experienced incorrect storage of drug (Verbatim: administered a dose of Boostrix to patient after the temperature excursion). The outcome of the incorrect storage of drug was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date 18-NOV-2025 Nurse called to report a temperature excursion for Boostrix, and they administered a dose of Boostrix to a patient after the temperature excursion. The temperature was 50-degree F for 2 days (less than 72 hours), also stated that there was no prior excursion. Reporter requested stability information for the vaccine. This case is one of the five linked cases reported by the same reporter.; Sender's Comments: US-GSK-US2025AMR150126:Original Case Number : US2025149762 same reporter case for Havrix, US-GSK-US2025AMR150125:Original Case Number : US2025149762 same reporter case for Twinrix US-GSK-US2025AMR150124:Original Case Number : US2025149762 same reporter case for Fluarix US-GSK-US2025AMR150127:Original Case Number : US2025149762 same reporter case for Engerix-B